Frankfurt - Delayed Quote EUR

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (RIG2.F)

26.56
+0.06
+(0.23%)
At close: May 19 at 8:02:58 AM GMT+2
Loading Chart for RIG2.F
  • Previous Close 26.50
  • Open 26.56
  • Bid 25.78 x 100000
  • Ask 26.38 x 100000
  • Day's Range 26.56 - 26.56
  • 52 Week Range 22.94 - 28.32
  • Volume 200
  • Avg. Volume 324
  • Market Cap (intraday) 4.844B
  • Beta (5Y Monthly) 0.32
  • PE Ratio (TTM) 8.20
  • EPS (TTM) 3.24
  • Earnings Date Aug 6, 2025
  • Forward Dividend & Yield 1.25 (4.72%)
  • Ex-Dividend Date Jun 3, 2025
  • 1y Target Est --

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products in Europe, the Asia Pacific, North and Latin America, and internationally. It operates through two segments, Pharmaceuticals; and Wholesale and Retail. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. The company was formerly known as Gedeon Richter Ltd. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.

www.gedeonrichter.com

10,943

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RIG2.F

View More

Performance Overview: RIG2.F

Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

RIG2.F
6.50%
MSCI WORLD (^990100-USD-STRD)
4.19%

1-Year Return

RIG2.F
106.63%
MSCI WORLD (^990100-USD-STRD)
11.58%

3-Year Return

RIG2.F
100.05%
MSCI WORLD (^990100-USD-STRD)
45.38%

5-Year Return

RIG2.F
100.00%
MSCI WORLD (^990100-USD-STRD)
87.27%

Compare To: RIG2.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RIG2.F

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    4.79B

  • Enterprise Value

    4.34B

  • Trailing P/E

    8.17

  • Forward P/E

    7.02

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.23

  • Price/Book (mrq)

    1.45

  • Enterprise Value/Revenue

    1.99

  • Enterprise Value/EBITDA

    4.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.24%

  • Return on Assets (ttm)

    10.18%

  • Return on Equity (ttm)

    18.81%

  • Revenue (ttm)

    878.14B

  • Net Income Avi to Common (ttm)

    239.17B

  • Diluted EPS (ttm)

    3.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    201.78B

  • Total Debt/Equity (mrq)

    6.29%

  • Levered Free Cash Flow (ttm)

    108.83B

Research Analysis: RIG2.F

View More

Company Insights: RIG2.F

Research Reports: RIG2.F

View More

People Also Watch